This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good morning ladies and gentlemen and welcome to Kovalon's Q2 fiscal 2022 conference call and webcast. My name is Michelle and I will be your conference operator today. As a reminder, today's conference is being recorded. All lines have been placed on mute to prevent any background noise and after the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, press star then the number one on your telephone keypad if you would like to withdraw your question please press the star followed by the number two alternatively you can submit typed questions via the webcast at this time I would like to turn the conference over to mr. Brian peddler president and chief executive officer and mr. Jason Gorel interim chief financial officer and Please go ahead, Mr. Pedler and Mr. Gorel.
spk01: Thanks, Michelle. Good morning, fellow investors. Thank you for joining us in this call. Emily Hill from Covalon is helping to coordinate the conference call and webcast, and she will now provide us with some instructions.
spk08: Thanks, Brian. Good morning, everyone. My name is Emily Hill. I'm the Executive Assistant to Covalon's Chief Executive Officer. I'd like to thank everyone for taking the time this morning to attend our conference call and webcast. We will be discussing the financial statements, MD&A, and press release related to Covalent's second quarter, ended March 31, 2022. There will be an opportunity for you to ask questions at the end of our call. So before we begin the discussion, I would like to remind participants that this call and webcast are covered by Covalent's Safe Harbor Statement. Certain statements included on this conference call may be considered forward-looking. Such statements involve known and unknown risks. uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from those implied by our statements, and, therefore, these statements should not be taken as guarantees of future performance or results. All forward-looking statements are based on management's current beliefs, assumptions, and information currently available to us and related to anticipated financial performance, business prospects, partnership opportunities, strategies, regulatory developments, market acceptance, and future commitments, among other things. Participants on this conference call are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call. Due to risks and uncertainties, including those identified by COGLON in our public security filings, actual events may differ materially from current expectations. COGLON disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. In the management's discussion and analysis, press release, and in this call, Covalent has provided non-IFRS measures that are meant to provide further understanding of our results by helping to highlight trends and assist in comparing different periods. The adjusted gross margin and adjusted EBITDA are terms that do not have any standardized meaning and may not be comparable to other companies. These measures are not meant to replace the similar IFRS measures, and any adjusting items may recur in the future. I will now turn the call back over to you, Brian.
spk01: Thanks, Emily. I'm going to walk through the quarterly numbers and provide some context as well as talk about some of our growth objectives underway in 2022 and beyond. Then both Jason and I will take your questions either through the phone line or via the message function on the webcast. So there are three key focus areas that I want to draw your attention to before we review our quarterly results. Number one, we have a financially strong core business, not only with our balance sheet, with our cash position and no debt, but we also have a very strong management team. Our innovative products are backed by very strong intellectual property and also supported by the clinicians that use them in the market. They're just better products. And then the third item is that we are in a There's massive growth potential in the markets that we focus on in the United States and worldwide in the areas of infection prevention and helping patients heal. And those are really important fundamentals of Covalon. So moving on to the financial results, looking at our, you know, at our results to date this fiscal year, we are ahead on revenue for the first six months. Revenue from continuing operations for the six months ended March 31, 2022 was $8.2 million, which is 19% growth over the same period last year. This year-to-date growth is predominantly driven by increased product sales into our core market, which is the United States. We continue to see strong growth opportunities for our key products in the U.S., for both our collagen and our infection prevention products. As we are all aware, during the quarter ended March 31, 2022, the Chinese government imposed severe restrictions on Shanghai businesses that resulted in significant restrictions on the ability for companies to manufacture and ship products out of Shanghai. We were negatively affected by these restrictions as were most worldwide supply chains. This resulted in delays in product shipments from our warehouse in Shanghai, and our second quarter revenue was $3.3 million as a result. We are in the fortunate position of being able to withstand this temporary supply chain disruption. We have a very strong balance sheet with $22 million of cash as of March 31, 2022, and no debt. Our customer base is very loyal, and our customers simply love our products. Even with our shipment delays, they continue to be vocal champions for Kovalon. In addition to being ahead of last year's revenue by 19%, despite the shipping restrictions in Q2, our gross profit margin once adjusted for revenue provisions was 60% for the first six months. Our efforts to improve our operations are having a positive impact on our gross margin. Because of the delays in shipments in Q2, our gross margin for the gross profit margin for the quarter was 1.7 million compared to 2 million in Q2 fiscal 2021. On an adjusted basis, our margin was 56%, which is up from last year's 54%.
spk06: Margin is heavily influenced by product mix and any inventory provisions booked in a quarter.
spk01: Turning to our Q2 revenue, for the reasons we discussed around delays in shipping, product revenue came in at $3 million compared to $4 million in the same period in the prior year. We are still seeing very strong demand for products in both the United States and in our international markets. I'm very encouraged with the current activity we are seeing in our hospital customer base and our collagen distribution channels in our international markets. The United States continues to be our dominant market. Our sales and clinical teams are highly focused on converting our sales funnel of major hospitals that have recognized that our IVClear, ValGuard, and SurgiClear products can solve real clinical problems associated with unwanted infections for intensive care units and surgical patients. We are also seeing growth opportunities around our collagen products, including our collagen powder that we launched in 2021. We have invested in improvements to our supply chain. and our manufacturing capabilities in order to efficiently meet the increasing demand for our products that we're seeing. In our commercialization facility in Mississauga, we manufacture our recently launched collagen powder and collagen dressings to meet increased market demand. By being able to manufacture in-house certain products, we are able to gain better margins on those products than with using contract manufacturers. Our investments to help improve margins are paying off and we are beginning to see some impact from our efforts as our gross margins on an adjusted basis are up over last year. Our operating expenses are up year over year. As we have previously talked about on other calls, we are investing in building our sales and marketing resources so we can accelerate our growth opportunities in the United States, where we have a solid base of hospital and college and customers. We also redeployed some very strong team members that were previously focused on our divested AquaGuard business to support our growing U.S. operations. We intend to continue to invest in accelerating our revenue growth in the United States, and we'll do so by making sure that we can recover our investments and resources and personnel in the shortest time possible. I am highly confident that we will achieve our growth objectives. As we previously announced, two experienced industry veterans joined Covalon, Ron Ebert as Senior Vice President of Marketing, and Mark Doolittle as Senior Vice President of Commercial Sales. Both Mark and Ron are very talented and experienced executives that have individually strong track records in creating value in medical companies. Ron, Mark, and I, along with the rest of the management team, are laser focused on building Covalon into the powerhouse it deserves to be given our unique life-saving medical technologies. I'm going to talk now a little bit about some growth drivers. This is one of the reasons that I believe Ron and Mark joined Covalon. We have world-class products that are sought after by clinicians and patients. We have the world's only dual antimicrobial surgical site dressing. the world's only dual antimicrobial silicone IV dressing, and the world's only vascular access line-to-line connection barrier. We are also the only company in the market currently with a collagen wound filler with antimicrobial silver. These products, as I mentioned, are supported by a portfolio of intellectual property, patents, and know-how that give Covalon a serious advantage with our product portfolio over other companies. Our products are better, and safer than our competitors. We see strong growth opportunities with our product solutions in the markets we address that have a clear path to substantial revenue over the next several years. We see strong opportunities to cross-sell our IvyClear and ValGuard products through our existing US customer base. We are already seeing additional contract opportunities internationally for vascular access technologies. Our advanced wound care portfolio, of which our collagen products are the flagship, have a long history of helping patients to heal when other products have been unable to help. The demand for our collagen in the United States continues to be strong, and our recently launched collagen powder allows us to open up new revenue opportunities in chronic and surgical wound healing. We have a solid base of reference hospitals in the United States that have demonstrated SurgiClear's ability to help reduce surgical site infections. As we launch SurgiClear into additional hospital and ambulatory surgical center channels, we also anticipate meaningful revenue growth from our perioperative care products. Even though our revenue for Q2 was below expectations due to circumstances beyond our control, I'm very encouraged with the growth prospects we are seeing in the second half of fiscal 2022. There is a significant need for cost-effective solutions for infection prevention and wound healing right now in the market. In a post-COVID world, both patients and clinicians are demanding better, safer products that protect them while they heal. Covalon is one of the select few companies that have products ready to be used today by clinicians to help solve these serious infection issues. We are a much stronger company today than a year ago. We strengthened our balance sheet and improved our operations since last year at this time. We also have a stronger, more talented leadership team. We have decided to use our strong cash position to further strengthen the company by intending to buy back up to 5% of Covalent's shares for cancellation. To this end, as previously announced, the company has filed its intention to make a normal course issuer bid, or NCIB, for its common shares with the TSX Venture Exchange, which is subject to regulatory approval. While we will no doubt face challenges in the future, and not everything is in our control, I can say for certain that our team at Covalent is working harder than ever to grow our business and continue the positive progress we have made to date. These improvements are already positively impacting our growth prospects, and Koblon is well positioned to take advantage of growth opportunities in 2022 and 2023. I would now like to open the line for questions. I ask that you try to keep to one or two questions at a time if you're calling in, and there will be lots of time to get back in the queue to ask more. Please also feel free to use the chat function in the webcast. I'll turn it back over to you, Michelle.
spk07: Thank you, sir. Ladies and gentlemen, we will now open the floor for questions. As a reminder, if you would like to ask a question at this time, simply press star, then the number one on your telephone keypad. If you would like to withdraw your question, please press the star, followed by the number two. Alternatively, you can submit typed questions via the webcast. Please stand by for your first question. Your first question comes from Sapir Menachery of 8 Capital. Please go ahead.
spk02: Good morning, and congrats on some of the recent impressive hires. Just a question on the timing of the delays with the shipments. Is that something that you've gained visibility on? Is that basically orders that are going to be pushed forward to the next quarter, or do you see ongoing delays, and are things getting kind of... pushed over or those lost orders and what visibility do you have on Q2, I guess?
spk01: Yeah, thanks, Sep. Appreciate the question. The orders, what happened in Shanghai specifically was basically all the facilities, manufacturers as well as warehouses were shut. People were not allowed to go to work. So shipments that we had sitting waiting to go in March could not be shipped out. Those restrictions have stayed in place and have recently been lifted, so those shipments are now going. I don't consider it lost. It's delayed.
spk02: Understood. Do you expect, I guess, relative to the quarter prior to this, do you expect to see this backlog, let's call it, to cause a quarter-over-quarter growths above what was previously a $20 million run rate?
spk01: Well, what happens is these are consumed products. So there's order patterns in our distribution chain, including at hospitals, and the products need to get consumed and reordered. And so there will be... some impact that gets pushed forward into quarters going beyond the quarter that we're in right now. But in general, I would say it's not lost business.
spk02: Understood. That's great. And just on the recent hires, is the focus to really have them lead the scaling in the U.S., or is the focus right now some of these international markets, specifically, I guess, some of the legacy ones like Saudi Arabia, some of the other regions that you've talked about.
spk01: Yes, we have good strong distribution channels into our international markets. And so although our team is looking at Ron and Mark specifically in our marketing and sales teams, are looking at the world in total. The real focus is growing our U.S. presence where we see a lot of opportunity and we have a really strong base of both hospital customers and collagen distribution partners that we see opportunities to grow. So their main focus of the entire company is going to be growing in the United States. But obviously, we have solid distribution channels internationally as well.
spk02: And have you guys kind of internally come up with a number or a goal in terms of hospitals you're in now versus ones you want to get into? And is that something you can kind of ballpark?
spk01: Yeah, I think we're in a small fraction of the hospitals right now. I'd say we have probably 60 hospitals that are buying products from us. And that's 60 out of 6,000 that exist. So there's a huge growth opportunity for us. We have a good, solid platform. We're in some of the top children's hospitals that are world-class facilities. And when we're dealing with solving serious clinical problems with some of the most vulnerable patients, That position where we're able to do that in those facilities translates very well for our ability to solve those same issues in adult populations. I think leveraging our current position will help us accelerate that growth. We're adding hospitals on a continuous basis as customers, and we're trying to try to maximize our ability to solve the clinical infection problems in each facility. And that happens over time as well. So our business within our install base grows as well as us adding additional facilities.
spk02: Yeah, certainly great opportunity for growth there. Thanks for taking my questions today and congrats on the continued growth outlook.
spk06: Great. Thanks, Seth. I appreciate your questions. Your next question comes from Arnold Schell.
spk07: Please go ahead.
spk03: Yeah, just a follow-up from that question. When you bought Aquaguard, I thought you said it gave you entree into 1,500 hospitals. And just now you've said you have 60 hospitals that buy products from. What's the difference between the 1,500 and the 60?
spk01: Yeah, Arnold, good question. When we sold the AquaGuard product, those hospitals that were buying AquaGuard went with the transaction. We have contacts and relationships, but not all of the AquaGuard hospitals were also buying other Covalent products like IvyClear, ValGuard, or SurgiClear. You know, we have a good solid base, and we're trying to maximize our opportunity in those hospitals. And we have relationships and entry points into the historic Aquaguard install base, but we can't call those our customers if they're not buying, you know, our current colon products from us.
spk06: Your next question comes from Sal Detouris.
spk07: Please go ahead.
spk04: Hey, good morning, guys. I got my question in and it was very, very similar to the first question you answered, but I want to just be clear on one or two points. So I'd appreciate it if you could just give me a little additional info. I was questioning, again, your $3.3 million and the reason for that was major delays in product shipments from the warehouse in Shanghai. And you also mentioned that you're able to withstand this temporary supply chain disruption. The question I have, and I think you answered part of it already, is what is the current status of these disruptions and delays, and can we expect to see some of this flow through that didn't come through in the second quarter, in quarter three and four? I think you said some or most of these restrictions have been lifted. Is that correct?
spk01: Yes. Sal, it's a good clarification point. So, yes, the restrictions are lifting. You can imagine there's a bit of a backlog in Shanghai, not only with us, but all the other organizations that have warehouse facilities and factories there. Our shipments are moving now, and the products that are there will begin to move out. You know, again, I reiterate that some of these are consumable products, so they go to facilities they need to get consumed and then they reorder. So some of the business gets shifted beyond this current quarter into the following quarter. But in general, I don't view this as lost business at all.
spk04: So, okay, then should we expect to see, you know, improved revenues in Q3 and Q4?
spk01: Well, it's our intention. Again, you know you've been following Kovalon for quite some time, and we're not – I've got to be careful. We're not providing guidance, but based on what we see right now in our book of orders that we have and our shipments that are going out, I do see improvements going forward in our Q3 and Q4.
spk06: Thanks, Sal. I appreciate the questions.
spk07: Ladies and gentlemen, as a reminder, if you would like to ask a question, please press star followed by the one on your telephone keypad. Please limit yourself to one question per turn. Your next question comes from Jason Sinensky of Chapter 12. Please go ahead.
spk00: Hi, Brian. Thanks for taking my question. Sorry to belabor the Shanghai issues, but just wanted to go back there. I guess I wasn't aware that the company had any operations in Shanghai. Could you just provide a little more color on whether that's on the collagen side of the business, the antimicrobial side, and is it fair to assume that that operation is mainly or exclusively shipping into the Middle East?
spk01: Jason, it's a... It's mostly our wound care products. Our infection prevention products generally come out of the US, and so it's mostly our non-collagen-based wound care products that come out of the Middle East, or sorry, out of Shanghai, and they go all over. They go into all of our international, and as well, some into our North American channels.
spk06: Your next question comes from Arnold Schell.
spk07: Please go ahead.
spk03: Yeah, also about Shanghai. Why do we have a warehouse in Shanghai, and how long have we had it?
spk01: Arnold, we've had a warehouse there for seven, eight years, and it's because some of our products are manufactured in Shanghai. in Shanghai or outside of Shanghai and are shipped from there to various parts of the world. We have contract manufacturers in the United States as well as in China. It happened that we got caught up in the government closures that happened there. Normally, we have a pretty strong supply chain and plan ahead. This was just out of our control.
spk06: Once again, ladies and gentlemen, if you would like to ask a question, please press star 1 now. Your next question comes from Joseph Shear.
spk07: Please go ahead.
spk05: Good morning. I'm confused. You speak about missed shipments as being often consumed, which I assumed you meant that a hospital would say, well, we use so much of a certain material over a week, a month, or whatever it is, so we order that. Of course, if you don't receive it, so many patients who had operations during which they might use some of this have had their operation, have left, and they're not returning. So it's not something that will add to, that will be recovered in sales later on. The hospital had a certain budget or forecast for the use of this, so it's consumed. It's like a restaurant. You can't say, well, you missed some, you had to close for a blizzard, and therefore you will recover those supplies you know, the meals that will be eaten, they're lost, they're gone. I thought that's what you meant by consumed, but yet you keep saying that, no, you'll recover these sales. Could you, am I, I'm confused, I guess.
spk01: Okay, Joseph, sorry, what I said was confusing. So you have to think of this as a supply chain. So we ship to our distribution partners that that tend to warehouse and then ship to hospitals that also tend to warehouse so The reason that it's a delay and and I don't view it as a loss is that our Our products are not just in time Consumed the day that they arrive at a facility. They're consumed over periods of time and so I The inventory that's in the distribution channel will drop below normal levels, but it doesn't mean that facilities run out of our product. The product will make its way to the facilities. There may be some that where the product levels within the hospitals and our distributor warehouses fall extremely low. But in general, I think with the delay that we've had of a couple months on these shipments, unfortunately, it fell out of our revenue, but we will pick them up again, and they'll impact our revenue going forward in a positive way. So there is a supply chain that has a product in it, And that's why it's not really like meals in a restaurant. It is more like product sitting on shelves and in the back warehouse of a Walmart. So hopefully that helps explain it.
spk07: There are no further questions from the phone lines. At this time, I would like to turn the conference back to Emily Hill. Please go ahead.
spk08: Hi, I'll read our first questions from the webcast. This first question comes from Jason Sininsky at Chapter 12 Capital, who asks to please discuss priorities for Ron and Mark in their first year with the company.
spk01: Yeah, thanks, Jason, for the question. Ron and Mark and the entire team are focused on a a few key areas. One is immediately helping to grow our top line revenue. We're also implementing much stronger digital engagement with our clinicians so we can educate and support and train them in a manner that's as efficient as possible. as well as to use their experience in order to look at further opportunities for us to penetrate the market with our current products and set ourselves up for growth going forward as we look at additional opportunities to leverage our products into treatment areas that we're currently not focused on.
spk06: I appreciate the question. Sorry.
spk08: Our next question comes from Dave Kiegler, who asks, you mentioned that the decrease in revenue was a result of government restrictions in Shanghai relating to COVID-19, which adversely reduced the company's ability to ship products to customers. My question is, if there were no restriction or supply chain issues, what do you estimate your revenue would have been, and do you see this continuing into the next quarter?
spk01: Yeah, thanks, Dave. Really appreciate the question. I don't foresee the supply chain issue specifically that we faced in Shanghai continuing into this quarter that we're currently in. And I think we'll just stay tuned and see what our numbers are that we release as of our June quarter. I'm not going to speculate on where we would have been I don't think that's fair but I certainly appreciate the the question and you know I think I think we'll see going forward that we're more you know our quarters are more in line with where we all anticipated they would be thanks Dave appreciate that question
spk08: We have three questions from Howard Petrick, private investor. He asks, why is there almost a total lack of interest in the stock? What efforts are being made to market it to a wider audience? And why is there an absence of analyst coverage from major houses?
spk01: Howard, thanks for the questions. I don't believe there's a total lack of interest in the stock. We are a thinly traded stock. But I get a lot of interest from shareholders. I talk to shareholders every day, both current and potential shareholders. So we are attending a lot of shows. I've attended several of them and have several more coming up where we are. They're investor shows. And as far as analysts, I think you've heard on the phone there's been several – that are asking questions on these calls and are beginning to follow the company. So I think we're making progress on that front. But I certainly appreciate the questions.
spk08: We have a question from Arnold Shell who asks, for the normal course issuer bid, does the stock price have to fall further before you start the purchases?
spk01: Arnold, no. We're simply just waiting for the approval from the TSX Venture Exchange, and as soon as we receive that, there's a short waiting period of a couple days, and then we will begin the process. I think we all feel that the value of Covalon is not aligned with its stock price, and so a good use of our capital currently is to reduce the number of outstanding shares. So we'll be moving forward aggressively on the NCIB as soon as we are able to do so.
spk08: We have a series of questions from a private investor. who asks, have sales slash supplies normalized yet given the COVID restrictions in China? Did Covalon lose customers as clients thought other suppliers or have sales normalized? Why don't we start with those two and then we'll get to the second half of the questions after.
spk01: Yeah, so I think we've talked a lot about Shanghai and the issues there, so I'm not going to readdress that. I don't think we've lost any customers. I think, in fact, we've beginning to gain and are gaining customers. We are in a lumpy business where our shipments internationally tend to be lumpy as we ship large containers full of product. In the United States, as we look at our hospital business, that's a little bit more steady, but right now our quarterly revenue can swing based on when shipments leave. And we saw that we had planned a significant number of shipments going out that didn't make it into our Q3. So I think increased prospects. The world has changed as far as how medical products companies engage with hospitals. Before COVID, 70% of the sales done in our industry were face-to-face. Now that's reversed, and a lot of engagement is happening virtually and digitally, but we're also obviously still able to get into facilities and engage one-on-one, but our preference is to engage clinicians and facilities in the most efficient way possible, and so that's really where I see the opportunity for our growth going forward, and that's one of the reasons that Ron has joined the organization. He's got a strong background in engaging with clinicians digitally and through multi-channels in the U.S. market.
spk08: This investor also asks, how much of an increase in collagen production capacity has there been as a result of investment?
spk01: I think there's been a significant... We have a patented process of making our product that allows us to... you know, expand production without major investments in capital equipment. And so I think we have a good strong capacity right now and we will continue to grow that as we see the business growth prospects continue over the next 12 months. We have a pretty good visibility into that marketplace and I'm really encouraged with with our ability to manufacture cost-effectively and our capacity within that part of our supply chain.
spk08: Our next question comes from Arnold Shell, who asks if Covalent is looking to alternatives to China to mitigate risks going forward.
spk01: Again, I think this is a temporary issue, Arnold. Changing suppliers and contract manufacturers of medical devices requires regulatory processes that take a certain period of time. I think we are comfortable that this situation we face was temporary, and I think we're largely through it. We are always on the lookout for better, safer products for our patients, but right now I think we have a pretty good relationship with our partners there, and I don't foresee that we're going to have the same issues going forward.
spk08: Our next question comes from John, private investor, who asks, over the years, you've had a few big deals like the ones with Momlica and the Saudi Arabia deal. Unfortunately, both have not produced the initial results expected. Do you expect any large contracts like these to occur in the future?
spk01: We're always engaging with large medical partners that are interested in our products, and we have the option with some of our technologies to license them where we don't think we have the opportunity or it's not the best use of our resources to exploit them directly in the market. So we're continuously talking to large companies about opportunities, whether that's distribution or otherwise, with our partners. with our platform technologies. It's one of the benefits of Kovalon that we have such a depth of products and intellectual property that there's lots of opportunities for us in order to unlock that value in different ways. So that is still part of our business model and we see opportunities and are engaging with organizations. Those tend to take a long period of time to come to fruition. And, you know, we don't, it's not our main focus at this point, but it can certainly move our needle rather quickly when we do enter into one of these lucrative opportunities.
spk08: Our next question comes from Trevor Holdinger at Aspen Wealth, who asks, Mark Doolittle has experience with U.S. healthcare groups, purchasing organizations, and integrated delivery networks, CPOs and IDNs, respectively. Can you discuss these networks and how this can expand sales?
spk01: Sure, Trevor. Great question. I really appreciate it. There's sort of two tracks that we have to follow in order to be successful with U.S. hospitals. And one of those is engaging clinically with the physicians, nurses, and other clinicians that are going to use our products on patients. And the other is working with the the C-suite, the group purchasing organizations, as you've identified in IDNs, that are contracting products from medical companies. And so we have to hit on both of those in order to be successful. And Mark certainly brings a lot of experience in engaging at that level, and I see this as a way for us When we do get clinical clinicians to really champion our products, we now have the opportunity to attack these revenue sources from both the clinical and the business side, which I think is necessary for us to accelerate our growth. Certainly, Mark has experience there, as does Ron, and I'm really looking forward to the opportunity to engage with these organizations differently than just strictly through a clinical means. Great observation and great question, Trevor. I really appreciate it. Looks like we're out of questions. I really appreciate everyone's participation in today's call. I'm confident that the fundamental improvements that we've made to Kovalon and our progress to date are going to demonstrate the significant unrealized value for our shareholders that I believe currently exists in Kovalon. And I can assure you that we are working very hard and are laser focused on building value in the company. And I look forward to discussing our progress on our next call. Thank you for attending today's call.
spk07: Ladies and gentlemen, this concludes your conference call for today. We would like to thank you for participating and ask that you please disconnect your lines.
Disclaimer